TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

Michael Osso is chief executive officer of the Crohn's & Colitis Foundation. "Eli Lilly Receives FDA Approval for Crohn's Disease Treatment," at 4:40 p.m. ET, and in a subsequent update, incorrectly ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...

Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Berenberg analyst Kerry Holford lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,050 and keeps a Buy rating on the shares.

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

The move comes more than 30 years since the Food and Drug Administration prohibited the use of Red No. 3 in cosmetics after ...